Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
22. November 2024 16:45 ET
|
Ocean Biomedical, Inc.
PROVIDENCE, Rhode Island, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on November 18, 2024, it received a notice from The Nasdaq Stock Market LLC...
Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter
22. Oktober 2024 16:45 ET
|
Ocean Biomedical, Inc.
PROVIDENCE, Rhode Island, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on October 16, 2024, it received a Staff Determination Letter from The Nasdaq...
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
23. August 2024 16:30 ET
|
Ocean Biomedical, Inc.
PROVIDENCE, Rhode Island, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on August 19, 2024, it received a notice from The Nasdaq Stock Market LLC...
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
30. Mai 2024 07:44 ET
|
Ocean Biomedical, Inc.
PROVIDENCE, Rhode Island, May 30, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on May 22, 2024, it received a notice from The Nasdaq Stock Market...
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K
24. April 2024 16:51 ET
|
Ocean Biomedical, Inc.
PROVIDENCE, Rhode Island, April 24, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on April 18, 2024, it received a notice from The Nasdaq Stock Market...
Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL
28. März 2024 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, March 28, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research...
Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody
05. Dezember 2023 08:15 ET
|
Ocean Biomedical, Inc.
Results published in the Journal Immunity share discovery of a new mechanism by which Chi3L1 regulates breast cancer development and progression PROVIDENCE, Rhode Island, Dec. 05, 2023 (GLOBE...
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
29. November 2023 17:41 ET
|
Ocean Biomedical, Inc.
PROVIDENCE, Rhode Island, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on November 22, 2023, it received a notice from The Nasdaq Stock Market...
Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients Worldwide
12. Oktober 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, Rhode Island, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top...
Ocean Biomedical (NASDAQ: OCEA) Share Price Target Now Averaging $18.21, Based on Research and Development Progress in Three Promising Programs Generating Novel Treatment Candidates for Cancer, Malaria, and Fibrosis.
09. August 2023 08:31 ET
|
Ocean Biomedical, Inc.
Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr. Jack A. Elias, MD and Dr. Jonathan Kurtis, MD, PhD on September 14, 2023 Providence, RI, Aug. ...